Jim Cramer on Recursion: "I Need to See a Proof of Concept Here"

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks on Jim Cramer’s radar recently. When a caller asked about the stock during the lightning round, Cramer stated:

“I don’t know. It’s been such a dog. It’s been a dog, we had them on, twice the price. It’s done absolutely nothing. I need to see a proof of concept here. I absolutely know that NVIDIA’s in it, but you know what? This, this, this stock has been a bad stock. We need to see something good before I tell you I would put any money in it.”

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical-stage biotech company using technology-driven approaches to accelerate drug discovery, with a pipeline targeting conditions such as cerebral cavernous malformation, neurofibromatosis type 2, familial adenomatous polyposis, C. difficile infection, and certain cancers. When a caller asked about the stock during a March episode, Cramer suggested to “hold off.” He said:

“Well, I’ll tell you… I’m reticent to put to, to really just to pull the trigger on Recursion because when they came on it was, it looked like at a good level and since then it’s just been disastrous. We’re going to have to hold off. I gotta meet them face to face and see what’s going on.”

Since the above comment, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stock is down by about 30%.

While we acknowledge the potential of RXRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.